Download PDF
Aktuelle Neurologie 2018; 45(04): 253-262
DOI: 10.1055/s-0043-125141
Übersicht
© Georg Thieme Verlag KG Stuttgart · New York

Therapiestandards und individualisierte Therapie bei der Myasthenia gravis

Myasthenia gravis: Treatment Standards and Patient-Tailored Therapy
Peter Paul Urban
1   Asklepios Klinik Barmbek, Neurologie, Hamburg
,
Christian Jacobi
2   Neurologische Klinik, Krankenhaus Nordwest GmbH, Frankfurt am Main
,
Sebastian Jander
3   Klinik für Neurologie, Universitätsklinikum Düsseldorf
› Author Affiliations
Further Information

Publication History

Publication Date:
03 May 2018 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Für die Myasthenia gravis stehen eine Reihe gut etablierter Therapiestandards zur Verfügung, die sowohl die symptomatische Therapie mit Acetylcholinesterasehemmern als auch eine breite Palette immunologisch-basierter Therapien umfassen. Hiermit lässt sich bei der Mehrzahl der Patienten ein gutes Therapieergebnis mit weitgehender Beschwerderemission erzielen. Für die optimale individualisierte Therapie bietet die Behandlung in spezialisierten Myastheniezentren mit der Integration ambulanter und stationärer Infrastruktur und breiter interdisziplinärer Kompetenz entscheidende Vorteile.

Abstract

For myasthenia gravis, a wide array of established treatment options is currently available. These include cholinesterase inhibitors for symptomatic treatment and a broad spectrum of immunosuppressive, immunomodulating or cell-depleting options to modify the underlying immunological process. Appropriate use enables a great majority of patients to lead a normal life. For optimum patient-tailored therapy, specialized centres integrating outpatient and inhospital resources as well as interdisciplinary competences offer decisive advantages.

Schlüsselwörter

Myasthenia gravis - neuromuskuläre Übertragungsstörung - Therapie

Keywords

myasthenia gravis - neuromuscular disorder - treatment
 

  • Literatur

  • 1 Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol 2015; 14: 1023-1036
    CrossrefPubMedGoogle Scholar
  • 2 Aeschlimann JA, Reinert M. Pharmacological action of some analogues of physiostigmine. J Pharmacol Exp Ther 1931; 43: 413-444
    PubMedGoogle Scholar
  • 3 Remen L. Zur Pathogenese und Therapie der Myasthenia gravis pseudoparalytica. Dtsch Z Nervenheilkunde 1932; 128: 66-78
    PubMedGoogle Scholar
  • 4 Walker MB. Treatment of myasthenia gravis with physostigmine. Lancet 1934; 1: 1200-1201
    PubMedGoogle Scholar
  • 5 Nair VP, Hunter JM. Anticholinesterases and anticholinergic drugs. Continuing Education in Anaesthesia, Critical Care & Pain 2004; 4: 164-168
    CrossrefPubMedGoogle Scholar
  • 6 Maggi L, Mantegazza R. Treatment of myasthenia gravis. Focus on Pyridostigmine. Clin Drug Investig 2011; 31: 691-701
    CrossrefPubMedGoogle Scholar
  • 7 Deutsche Gesellschaft für Neurologie (DGN). Leitlinien der DGN: Diagnostik der Myasthenia gravis und des Lambert-Eaton-Syndroms (29.06.2015). Im Internet: http://www.dgn.org/leitlinien/3005-ll-68-ll-diagnostik-und-therapie-der-myasthenia-gravis-und-des-lambert-eaton-syndroms
    PubMedGoogle Scholar
  • 8 Mehndiratta MM, Pandey S, Kuntzer T. Acetylcholinesterase inhibitor treatment for myasthenia gravis. Cochrane Database Syst Rev 2014; CD006986. DOI: 10.1002/14651858.CD006986.pub3.
    CrossrefPubMedGoogle Scholar
  • 9 Punga RA, Stalberg E. Acetylcholinesterase inhibitors in myasthenia gravis: To be or not to be?. Muscle Nerve 2009; 39: 724-728
    CrossrefPubMedGoogle Scholar
  • 10 Wolfe GI, Kaminski HJ, Aban IB. et al. Randomized trial of thymectomy in myasthenia gravis. N Engl J Med 2016; 375: 511-522
    CrossrefPubMedGoogle Scholar
  • 11 Pascuzzi RM, Coslett HB, Johns TR. Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients. Ann Neurol 1984; 15: 291-298
    CrossrefPubMedGoogle Scholar
  • 12 Schneider-Gold C, Gajdos P, Toyka KV. et al. Corticosteroids for myasthenia gravis. Cochrane Database Syst Rev 2005; 2: CD002828
    PubMedGoogle Scholar
  • 13 Seybold ME, Drachman DB. Gradually increasing doses of prednisone in myasthenia gravis. Reducing the hazards of treatment. N Engl J Med 1974; 290: 81-84
    CrossrefPubMedGoogle Scholar
  • 14 Palace J, Newsom-Davis J, Lecky B. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group. Neurology 1998; 50: 1778-1883
    CrossrefPubMedGoogle Scholar
  • 15 Gronseth GS, Barohn RJ. Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000; 55: 7-15
    CrossrefPubMedGoogle Scholar
  • 16 Iorio R, Damato V, Alboini PE. et al. Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis. J Neurol 2015; 262: 1115-1119
    CrossrefPubMedGoogle Scholar
  • 17 Hohlfeld R, Michels M, Heininger K. et al. Azathioprine toxicity during long-term immunosuppression of generalized myasthenia gravis. Neurology 1988; 38: 258-261
    CrossrefPubMedGoogle Scholar
  • 18 Hohlfeld R, Toyka KV, Besinger UA. et al. Myasthenia gravis: reactivation of clinical disease and of autoimmune factors after discontinuation of long-term azathioprine. Ann Neurol 1985; 17: 238-242
    CrossrefPubMedGoogle Scholar
  • 19 Pedersen EG, Pottegard A, Hallas J. et al. Myasthenia and risk of cancer: a population-based case-control study. Eur J Neurol 2014; 21: 773-778
    CrossrefPubMedGoogle Scholar
  • 20 Pedersen EG, Pottegard A, Hallas J. et al. Risk of non-melanoma skin cancer in myasthenic patients treated with azathioprine. Eur J Neurol 2014; 21: 454-455
    CrossrefPubMedGoogle Scholar
  • 21 Muscle Study Group. A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. Neurology 2008; 71: 394-399
    CrossrefPubMedGoogle Scholar
  • 22 Sanders DB, Hart IK, Mantegazza R. et al. An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology 2008; 71: 400-406
    CrossrefPubMedGoogle Scholar
  • 23 Hehir MK, Burns TM, Alpers J. et al. Mycophenolate mofetil in AchR-antibody-positive myasthenia gravis: outcomes in 102 patients. Muscle Nerve 2010; 41: 593-598
    CrossrefPubMedGoogle Scholar
  • 24 Meriggioli MN, Ciafaloni E, Al-Hayk KA. et al. Mycophenolate mofetil for myasthenia gravis. Neurology 2003; 61: 1438-1440
    CrossrefPubMedGoogle Scholar
  • 25 Hobbson-Webb LD, Hehir M, Crum B. et al. Can mycophenolate mofetil be tapered safely in myasthenia gravis? A retrospective, multicenter analysis. Muscle Nerve 2015; 52: 211-215
    CrossrefPubMedGoogle Scholar
  • 26 Lim AKH, Donnan G, Chambers B. et al. Mycophenolate mofetil substitution for cyclosporine-dependent myasthenia gravis and nephrotoxicity. Intern Med J 2007; 37: 55-59
    CrossrefPubMedGoogle Scholar
  • 27 Oskarsson B, Rocke DM, Dengel K. et al. Myasthenia gravis exacerbation after discontinuing mycophenolate. Neurology 2016; 86: 1-5
    CrossrefPubMedGoogle Scholar
  • 28 Heckmann JM, Rawoot A, Bateman K. et al. A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis. BMC Neurology 2011; 11: 97
    CrossrefPubMedGoogle Scholar
  • 29 Pasnoor M, He J, Herbelin L. et al. A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis. Neurology 2016; 87: 57-64
    CrossrefPubMedGoogle Scholar
  • 30 Braun J, Kaestner P, Flaxenberg P. et al.; MC-MTX.6/RH Study Group. Comparison of the clinical efficacy and safety of sucutaneous versus oral administration of methotrexate patients with active rheumatoid arthritis. Arthritis Rheum 2008; 58: 73-81
    CrossrefPubMedGoogle Scholar
  • 31 Nagane Y, Suzuki S, Suzuki N. et al. Two-year treatment with cyclosporine microemulsion for responder myasthenia gravis patients. Eur Neurol 2010; 64: 186-190
    CrossrefPubMedGoogle Scholar
  • 32 Tindall RSA, Rollins JA, Phillips JT. et al. Preliminary results of a double blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N Engl J Med 1987; 316: 719-724
    CrossrefPubMedGoogle Scholar
  • 33 Ciafoloni E, Nikhar NK, Massey JM. et al. Retrospective analysis of the use of cyclosporine in myasthenia gravis. Neurology 2000; 55: 448-450
    CrossrefPubMedGoogle Scholar
  • 34 Ponseti JM, Gamez J, Azem J. et al. Tacrolimus for myasthenia gravis: a clinical study of 212 patients. Ann NY Acad Sci 2008; 1132: 254-263
    CrossrefPubMedGoogle Scholar
  • 35 Cruz JL, Wolff ML, Vanderman AJ. et al. The emerging role of tacrolimus in myasthenia gravis. Ther Adv Neurol Disord 2015; 8: 92-103
    CrossrefPubMedGoogle Scholar
  • 36 Nagaishi A, Yukitake M, Kuroda Y. Long-term treatment of steroid-dependent myasthenia gravis patients with low-dose tacrolimus. Inter Med 2008; 47: 731-736
    CrossrefPubMedGoogle Scholar
  • 37 Eienbröker C, Seitz F, Spengler A. et al. Intravenous immunoglobulin maintainance treatment in myasthenia gravis: a randomized, controlled trial sample size simulation. Muscle Nerve 2014; 50: 999-1004
    CrossrefPubMedGoogle Scholar
  • 38 Liew WKM, Powell CA, Sloan SR. et al. Comparison of plasmapheresis and intravenous immunoglobulin as maintenance therapies for juvenile myasthenia gravis. JAMA Neurol 2014; 71: 575-580
    CrossrefPubMedGoogle Scholar
  • 39 Zinman L, NG E, Bril V. et al. IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. Neurology 2007; 68: 837-841
    CrossrefPubMedGoogle Scholar
  • 40 Kupersmith MJ, Latkany R, Homel P. Development of generalized disease at 2 years in patients with ocular myasthenia gravis. Arch Neurol 2003; 60: 243-248
    CrossrefPubMedGoogle Scholar
  • 41 Köhler W, Sieb JP. Hrsg. Myasthenia gravis. Bremen: Uni-Med Verlag; 2012
    Google Scholar
  • 42 Engel AG. ed. Myasthenia gravis and Myasthenic Disorders. Oxford: Oxford University Press; 2012
    Google Scholar